Docusign FQ4 2026: The Inflection That Isn't (Yet)
Docusign reported FQ4 2026 earnings and the narrative from management was unmistakable: IAM is working, the business is at an "inflection point," and acceleration is beginning.
The data tells a more nuanced story — one where genuinely promising signals failed to translate into growth acceleration, and a weakening dollar is doing more for the headline numbers than the new platform is.
Six Quarters of Operational Data
Before interpreting the story management is telling, the raw operational trajectory:
| Metric | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|
| Revenue ($M) | $755 | $776 | $764 | $801 | $818 | $837 |
| YoY Growth | 8% | 9% | 8% | 9% | 8% | 8% |
| Billings ($M) | $752 | $923 | $740 | $818 | $829 | $1,019 |
| YoY Growth | 9% | 11% | 4% | 13% | 10% | 10% |
| Dollar Net Retention | 100% | 101% | 101% | 102% | 102% | 102% |
| Customers >$300K | 1,075 | 1,131 | 1,123 | 1,137 | 1,165 | 1,205 |
| YoY Growth | 2% | 7% | 6% | 7% | 8% | 7% |
| International Rev ($M) | $212 | $219 | $217 | $233 | $242 | — |
| YoY Growth | 14% | 12% | 10% | 13% | 14% | — |
At first glance, this looks like a stable, predictable business. Revenue grows ~8% every quarter. Enterprise customers are expanding steadily. DNR improved from 100% to 102%. Billings growth is healthy at 10%.
But the headline numbers are hiding something.
The FX Mask
Strip out the currency tailwinds and the revenue picture changes materially:
| Q2 FY26 | Q3 FY26 | Q4 FY26 | FY27 Guide | |
|---|---|---|---|---|
| Reported Growth | 8.8% | 8.4% | 7.8% | ~8.2% |
| FX Tailwind | ~0pp | +0.5pp | +0.8pp | +1.6pp |
| Constant Currency Growth | ~8.8% | ~7.9% | ~7.0% | ~6.6% |
Constant currency growth has dropped nearly 200 basis points in three quarters — and management's own FY27 guidance implies it continues declining to ~6.6%. The weakening dollar is the primary reason the 8% headline holds steady.
Docusign's CFO essentially acknowledged this on the Q4 call, noting that "after adjusting for impacts from FX and the moderate tailwinds from digital add-ons in fiscal 2026, revenue growth is in line with the prior year." Underlying growth hasn't accelerated at all.
IAM: Transformation or Platform Migration?
IAM scaling from $70M to $353M in ARR during FY26 — roughly 11% of total ARR in just 18 months — is genuine product traction. But the company-level math complicates the story considerably.
- Net new IAM ARR in FY26: $283M
- Total net new company ARR in FY26: $242M
The $41M gap means non-IAM ARR declined during the year. A meaningful portion of IAM's growth represents existing eSign customers migrating to IAM pricing — a platform shift, not purely incremental business.
For FY27, management guides total ARR to ~$3.55B (8.5% growth, up from 8.0% in FY26) with IAM reaching ~18% of the total, or roughly $639M. That implies IAM adds another ~$286M of net new ARR — essentially flat with FY26. The marginal "acceleration" from 8.0% to 8.5% comes primarily from the non-IAM base stabilizing (less drag), not from IAM growing faster.
The Leading Indicators That Didn't Translate
What makes the Q4 results particularly revealing is what preceded them.
Through mid-FY26, the setup looked genuinely promising. Dollar net retention had improved four full points from its 98% trough to 102% — a meaningful and sustained recovery in customer health. Enterprise customers spending over $300K were growing at their fastest rate in more than two years. Envelope utilization hit multi-year highs. International revenue crossed 30% of total for the first time, growing 14% year-over-year. Free cash flow growth accelerated sharply, from negative territory to +25% YoY.
The forward expectation was reasonable: if retention is improving, enterprise metrics are accelerating, and utilization is expanding, revenue growth should eventually follow.
It didn't.
By Q4, revenue growth sits exactly where it was. DNR has flatlined at 102% for three consecutive quarters — management expects "another year of modest improvement," but the plateau looks more like a ceiling than a waypoint. Enterprise customer growth (>$300K) actually decelerated from 8% YoY in Q3 to 7% in Q4. The leading indicators either stalled or failed to compound into top-line acceleration.
This doesn't mean the improvements were meaningless — DNR recovering from 98% to 102% is a legitimate stabilization of the core business. But stabilization is not acceleration, and it's important to be precise about what the data actually showed versus what investors (and management) inferred from it.
The Disclosure Problem
At the same time that management elevated the rhetoric, it reduced reporting transparency.
Billings — a metric where Docusign consistently beat its own guidance by 2-5% — is being retired. Quarterly ARR breakdowns are being dropped. Subscription revenue, previously guided separately, is folding into total revenue only. The company went from four top-line guided metrics to two.
Management frames this as "improving investor understanding." But quarterly net new ARR would be more transparent than annual-only disclosure. Their stated reason for avoiding quarterly ARR — "timing volatility" — is the same argument they used against billings.
When a company reduces the data available to verify its narrative at the exact moment it asks investors to believe an acceleration story, that gap between transparency and rhetoric deserves weight in any assessment.
What's Solid and What to Watch
The business fundamentals are genuinely strong. Docusign generates $1.06B in annual free cash flow — up 25% year-over-year. Non-GAAP operating margin crossed 30% for the first time. Billings consistently exceeded guidance, suggesting real demand that the disclosure changes will make harder to track going forward. IAM early renewal cohorts reportedly show better-than-average gross retention, which — if it holds at scale — could eventually drive the retention expansion the thesis requires.
This is not a broken company. It's a $3.2B revenue business with excellent unit economics and a product platform that has genuine market pull.
But the "inflection point" rhetoric is running approximately 2-3 quarters ahead of the evidence:
- Constant currency revenue growth is decelerating, not accelerating
- Net retention has plateaued, not continued improving
- IAM's growth is substantially substitutive, not purely additive
- The guided ARR "acceleration" (8.0% → 8.5%) is marginal, driven by base stabilization
The real test comes in FY27. The first full year of enterprise IAM renewal cohorts will either validate or undermine the expansion thesis. If IAM can drive genuine incremental growth — pushing total ARR growth above 10% while constant currency revenue stops decelerating — the inflection narrative becomes credible.
Until then, Docusign remains what the constant currency numbers say it is: a stable, mid-single-digit organic grower with excellent cash generation and a compelling but unproven transformation story. The data hasn't caught up to the narrative — and now there's less data to check.